Skip to main content

Epigenomics' 2008 Revenues Flat Year over Year; Net Loss Declines

NEW YORK (GenomeWeb News) – German molecular diagnostics firm Epigenomics today reported fiscal-year 2008 revenues of €2.6 million (US$3.4 million), flat with revenues of €2.6 million for 2007.

The company's FY 2008 net loss dropped 7 percent to €12.3 million, or €.47 per share, from €13.2 million, or €.74 per share.

The firm noted that its R&D costs declined 5 percent to €10 million from €10.5 million year over year.

Epigenomics said that it and Abbott are in the final stages of development and clinical validation of the firm's mSEPT9 assay for colorectal cancer. The test is on track for a fourth-quarter 2009 launch in Europe followed by the filing for US approval that is planned for 2010, said Epigenomics.

The Berlin-based firm also has a partnership with clinical lab giant Quest Diagnostics to develop and launch a laboratory-developed test version of the mSEPT9 assay.

Epigenomics finished the year with €12.1 million in liquid assets.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.